Treats overactive bladder with symptoms of urge urinary incontinence, urgency, and…. ANDA 210688, held by Msn. Solifenacin Succinate.
As of Nov 16, 2026, ANDA 210688 (Solifenacin Succinate), held by Msn, was first approved by FDA on May 20, 2019, with 2 approved supplements and 0 published complete response letters.
Solifenacin succinate tablet is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 20, 2019 | Original application | Approved | None posted |
| Solifenacin Succinate5MG · tablet;oral | Solifenacin Succinate | Rx |
| Solifenacin Succinate10MG · tablet;oral | Solifenacin Succinate | Rx |
| Jan 26, 2022 | Supplement 5Labeling · Standard review | Approved | None posted |
| Sep 23, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| May 20, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters